(Adnkronos) - “All'ospedale Ca’ Foncello di Treviso dal 2023 abbiamo messo in atto un percorso per donne sane affette da mutazioni genetiche Brca 1 e Brca 2. Le opzioni sono due: interventi di profilassi chirurgica o un protocollo di sorveglianza che prevede l'ecografia transvaginale e il dosaggio del marcatore tumorale per le ovaie; mammografia, ecografia e risonanza magnetica al seno a cadenza semestrale”. Lo ha detto Grazia Artioli, oncologo medico Uos Oncologia ginecologica, ospedale Ca’ Foncello di Treviso, intervenendo a valle della seconda tappa di “Cambiamo Rotta”, il progetto di sensibilizzazione sul tumore ovarico patrocinato da Acto Italia, Alleanza contro il Tumore Ovarico e sponsorizzato da Gsk.
Category
🗞
NewsTranscript
00:00In the Cafoncello hospital, since 2023, we have set up a path for women and also for healthy men affected by genetic mutations,
00:17because BRCA1 and BRCA2, if this mutation has been found within their family,
00:24means that these subjects have been subjected to a genetic consultation,
00:29and then, through this path, the geneticist signals us the subject,
00:34who is then received in this ambulatory, where he can meet a dedicated oncologist,
00:41which would be me, then a dedicated gynecologist, a senologist,
00:47and at the first meeting with the patient, the healthy subject, because in reality he is not a patient,
00:53the options are explained, with which he can then face the path.
01:02The options can be of a surgical type, that is, to undergo a prophylactic treatment,
01:09that is, a healthy organ is removed before it is damaged,
01:13for women it is about the exportation of mammals or tubes and ovaries,
01:19for men there is no prophylactic surgery,
01:23or they can adhere to a surveillance protocol,
01:27which provides transvaginal echography with the dosage of the tumor marker every 6 months,
01:33and mammography, echography and magnetic resonance in the breast at a semestral rate.
01:41Sometimes it happens that patients, healthy women,
01:46initially adhere to a surveillance process,
01:52and then over the years they mature the awareness to undergo a surgical treatment.
01:59Currently, since 2023, we have received about 40 subjects,
02:06and we are at a good point, and surely these numbers can only increase over time.
02:14As for the treatment of the ovarian tumor, today we can say that research helps a lot,
02:21that important drugs have arrived, such as parpinibutors.
02:26Thanks to the advent of these drugs, the BRCA test has further developed,
02:32because before it was really a niche test.
02:35Before, a test was done only for families, now it is used for therapies.
02:39Sometimes you do the test because you have a drug that helps you if you have that mutation.
02:46If you don't have that mutation, you have a molecular profile that favors the use of drugs,
02:53the so-called parpinibutors.
02:55Today, for the ECRD positive, we can also use a combined formulation of parpinibutor and antiangiogenetic,
03:04and further drugs are coming from research.
03:07Therefore, the therapeutic algorithm of the ovarian tumor is certainly in continuous evolution.
03:12Every year we have something new, luckily, to offer to our patients.